• Who we are
    • ABOUT MEDICINES FOR EUROPE
    • PURPOSE AND OBJECTIVES
    • OUR VALUES – OUR 5 PILLARS
    • STRUCTURE
    • MEMBERS
    • BECOME A MEMBER
    • CODE OF CONDUCT
    • DISCLOSURE
    • Vacancies
  • PRIORITIES
  • Key topics
    • ACCESS
    • INDUSTRIAL POLICY
    • REGULATORY AND LEGAL FRAMEWORK
    • FALSIFIED MEDICINES
    • SUSTAINABILITY
    • ANTIMICROBIAL RESISTANCE
    • MEDICINE SHORTAGES
  • Publications
    • EXTERNAL RESOURCES
    • FACTSHEETS
    • INFOGRAPHICS
    • PODCAST
    • POLICY
    • REPORTS
    • VIDEOS
  • Newsroom
    • IN THE NEWS
    • PRESS RELEASES
  • Contact us
Login Login
Medicines for Europe
  • Generic medicines
    • Home
    • Medicines for Europe
      • Generic medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • Definition
      • THERAPEUTIC AREAS
      • GLOSSARY
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Related links
      • Contact us
    • Twitter
  • Biosimilar medicines
    • Home
    • Medicines for Europe
      • Biosimilar medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • DEFINITION
      • THERAPEUTIC AREAS
      • GLOSSARY
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
      • External resources
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Related links
      • Contact us
    • Twitter
  • Value added medicines
    • Home
    • Who we are
      • Value added medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • Definition
      • THERAPEUTIC AREAS
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Contact us
  • Events

Biosimilars 2025: A Turning Point for equitable access and EU competitiveness

4 December 2025

Related Posts

  • ‘Access Is A Right, Not A Privilege’ – Medicines For… 9 February 2026 The president of Medicines for Europe, Steffen Saltofte, says Medicines…
  • Biosimilars Market Review 2025 24 June 2025
  • EU policies must not push essential medicines off market:… 9 February 2026 President Steffen Saltofte argues that EU policy must protect timely…
  • EU Health Union has promise to deliver on equitable access… 30 May 2024 One of the key milestones of the current European Commission…
Medicines for Europe
MEMBER OF
IGBA EMVO
  • Contact us
  • Privacy Policy
Medicines for Europe AISBL
Rue d’Arlon 50
1000 Brussels Belgium
T : +32 (0)2 736 84 11
Powered by Big Smile Agency
Medicines For Europe
  • Who we are
  • Vacancies
  • PRIORITIES
  • Key topics – COVID-19
  • Publications
  • Newsroom
  • Contact us
  • SECTOR GROUPS
    • Generic medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
      • FIND OUT MORE
    • Biosimilar medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
      • FIND OUT MORE
    • Value added medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
  • Events
 Share This
 LinkedIn

Share on Mastodon

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok